Meeting Abstract


DOI :10.26650/JARHS2021-1142702   IUP :10.26650/JARHS2021-1142702    Full Text (PDF)

NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES

Semra DemokanSena ŞenÖnder EryılmazSevde CömertMurat UlusanMehmet Nejat Dalay

Objectives: Oral squamous cell carcinoma (OSCC) has a high morbidity and mortality rates, but there are no reliable biomarkers to define patients in early phases of disease. In our study (TUBITAK-SBAG-114S497), we aimed to investigate the potential epigenetic biomarker candidate genes observed methylation-dependent expression loss via methylation and expression array methods in OSCC patients. Material and Methods: Methylation and expression profiling in tumor and conjugate-normal tissue samples of 6 OSCC patients were analyzed by “IlluminaHumanMethylation450 chips” and “Illumina iScan”, respectively. Methylation/expression array data were analyzed and interpreted by R(v3.5.1) environment using ChAMP and limma/lumi packages, and then the significant decreased expression changes due to hypermethylation of the candidate gene was detected. The selected candidate gene was validated in tumor and matched-normal tissues and body fluids (serum and saliva) of 20 OSCC patients by QRT-PCR/QMSP methods. Results: According to the array results, it was determined that the expression levels of the candidate gene were decreased due to methylation (DiffScore:13.18826; FoldChange:-1.08345). This candidate gene (unpublished data), which plays an important role in ubiquitin-ligase activity, was found to be methylated in 45% tumor, 40% matched-normal tissue, 10% serum and 30% saliva samples. 50% of the patients observed methylation in the tumor tissue showed the differentially decreased expression levels. Conclusion: It is thought that this candidate gene, whose expression level decreased due to methylation, will be a candidate epigenetic biomarker for the early diagnosis of the subtypes of OSCC. Further validation of this candidate gene will be needed in the larger OSCC cohorts.


PDF View

References

    Citations

    Copy and paste a formatted citation or use one of the options to export in your chosen format


    EXPORT



    APA

    Demokan, S., Şen, S., Eryılmaz, Ö., Cömert, S., Ulusan, M., & Dalay, M.N. (2022). NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES. Journal of Advanced Research in Health Sciences, 5(1), 45-45. https://doi.org/10.26650/JARHS2021-1142702


    AMA

    Demokan S, Şen S, Eryılmaz Ö, Cömert S, Ulusan M, Dalay M N. NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES. Journal of Advanced Research in Health Sciences. 2022;5(1):45-45. https://doi.org/10.26650/JARHS2021-1142702


    ABNT

    Demokan, S.; Şen, S.; Eryılmaz, Ö.; Cömert, S.; Ulusan, M.; Dalay, M.N. NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES. Journal of Advanced Research in Health Sciences, [Publisher Location], v. 5, n. 1, p. 45-45, 2022.


    Chicago: Author-Date Style

    Demokan, Semra, and Sena Şen and Önder Eryılmaz and Sevde Cömert and Murat Ulusan and Mehmet Nejat Dalay. 2022. “NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES.” Journal of Advanced Research in Health Sciences 5, no. 1: 45-45. https://doi.org/10.26650/JARHS2021-1142702


    Chicago: Humanities Style

    Demokan, Semra, and Sena Şen and Önder Eryılmaz and Sevde Cömert and Murat Ulusan and Mehmet Nejat Dalay. NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES.” Journal of Advanced Research in Health Sciences 5, no. 1 (Feb. 2024): 45-45. https://doi.org/10.26650/JARHS2021-1142702


    Harvard: Australian Style

    Demokan, S & Şen, S & Eryılmaz, Ö & Cömert, S & Ulusan, M & Dalay, MN 2022, 'NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES', Journal of Advanced Research in Health Sciences, vol. 5, no. 1, pp. 45-45, viewed 24 Feb. 2024, https://doi.org/10.26650/JARHS2021-1142702


    Harvard: Author-Date Style

    Demokan, S. and Şen, S. and Eryılmaz, Ö. and Cömert, S. and Ulusan, M. and Dalay, M.N. (2022) ‘NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES’, Journal of Advanced Research in Health Sciences, 5(1), pp. 45-45. https://doi.org/10.26650/JARHS2021-1142702 (24 Feb. 2024).


    MLA

    Demokan, Semra, and Sena Şen and Önder Eryılmaz and Sevde Cömert and Murat Ulusan and Mehmet Nejat Dalay. NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES.” Journal of Advanced Research in Health Sciences, vol. 5, no. 1, 2022, pp. 45-45. [Database Container], https://doi.org/10.26650/JARHS2021-1142702


    Vancouver

    Demokan S, Şen S, Eryılmaz Ö, Cömert S, Ulusan M, Dalay MN. NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES. Journal of Advanced Research in Health Sciences [Internet]. 24 Feb. 2024 [cited 24 Feb. 2024];5(1):45-45. Available from: https://doi.org/10.26650/JARHS2021-1142702 doi: 10.26650/JARHS2021-1142702


    ISNAD

    Demokan, Semra - Şen, Sena - Eryılmaz, Önder - Cömert, Sevde - Ulusan, Murat - Dalay, MehmetNejat. NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES”. Journal of Advanced Research in Health Sciences 5/1 (Feb. 2024): 45-45. https://doi.org/10.26650/JARHS2021-1142702



    TIMELINE


    Published Online09.08.2022

    LICENCE


    Attribution-NonCommercial (CC BY-NC)

    This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


    SHARE




    Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.